WHO Panel Finds Insufficient Evidence To Review Kratom
The report said serious adverse effects were rare
An advisory committee of the World Health Organization (WHO) has concluded there is insufficient evidence to recommend a “critical review” of kratom, which potentially could have lead to international controls on the herbal supplement used by millions to treat pain and other medical conditions.
WHO’s Expert Committee on Drug Dependence (ECDD) recommended that kratom and its two active ingredients, mitragynine and 7-hydroxymitragynine, be kept under WHO surveillance. Under international treaties, WHO is required to give an annual assessment of psychoactive substances and advise the United Nations on whether they pose a public health risk.
The ECDD’s report said regular use of kratom can lead to dependence and mild withdrawal symptoms, but that serious adverse effects were rare. Kratom comes from the leaves of the mitragyna speciosa tree in southeast Asia, where it has been used for centuries as a natural stimulant and pain reliever.
To Read The Rest Of This Article On Pain News Network, Click Here
